Regulatory Climate Improves

BMI has reinforced its favourable assessment of Japan's regulatory environment after the country's Pharmaceuticals and Medical Devices Agency (PMDA) delineated a biosimilar approval pathway and promised to accelerate the time it takes to approve a new drug. In our Q207 Business Environment Rankings, we will continue to score Japan as nine for regulatory barriers as the country still has some way to go before it possess the most efficient, progressive and transparent monitoring system for pharmaceuticals in the Asia Pacific

To read the full article, please choose one of the following options: